The overexpression of CD73 is associated with various tumour types, such as breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, etc. Due to its crucial role in the regulation of key signalling molecules, CD73 is a significant and competitive target for the design of new, potent anticancer inhibitors. Here, NT5E is linked to Familial prostate cancer.